Research Topic · Peer-Reviewed

Myeloproliferative Disorders

Hematology and oncology research have made tremendous strides in the study of myeloproliferative disorders, a group of blood cancers characterized by excess growth of certain blood cells. These disorders include polycythemia vera, essential thrombocythemia, and primary myelofibrosis, all of which can lead to serious…

Curated from this journal's research 📚 4 peer-reviewed articles cited Cited 5× across the literature 🔖 ISSN 2372-6601 🗓 Reviewed June 2026

Overview

Hematology and oncology research have made tremendous strides in the study of myeloproliferative disorders, a group of blood cancers characterized by excess growth of certain blood cells. These disorders include polycythemia vera, essential thrombocythemia, and primary myelofibrosis, all of which can lead to serious complications such as strokes, heart attacks, and even transformation to acute leukemia. Research in the field of myeloproliferative disorders is focused on better understanding the underlying mechanisms of these diseases and developing effective targeted therapies. One area of investigation is the role of specific genetic mutations in driving abnormal blood cell growth. Scientists are also exploring how the bone marrow microenvironment contributes to the development and progression of these disorders. Treatment for myeloproliferative disorders relies on a variety of approaches, including chemotherapy, radiation, and bone marrow transplantation. However, there is always a need for safer and more effective treatment options, which is why ongoing research in this field is critical. Novel therapies such as JAK inhibitors have emerged as promising alternatives, although their long-term efficacy and safety are still being evaluated through clinical trials. Overall, hematology and oncology research in myeloproliferative disorders strive to improve the quality of life for patients and find a cure for these complex diseases. By providing greater insight into the biology of these disorders and developing new treatment strategies, researchers are making significant progress towards these goals.

Research published in this journal

4 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 4 articles above have been cited 5 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Myeloproliferative Disorders, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Jayadev Manikkam Umakanthan · United States Shuaiying Cui · United States Benedetto Sacchetti · Italy

This page summarises published research for orientation; it is not medical or professional advice.